Initiation of coverage POXEL | Corporate, TP EUR14 | Bringing new approaches to metabolic diseases
Poxel is a biotechnology company created in 2009 with assets and scientists from Merck Serono. It focuses on the treatment of metabolic diseases, particularly diabetes and NASH. Its originality lies in its main target, the mitochondrion. The latter is an important player in the homeostasis of glucose and fats by regulating the energy needs of our cells.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.